Suppliers / Hebei Changshan Biochemical Pharmaceutical

Hebei Changshan Biochemical Pharmaceutical

China Updated 9 July 2026

Hebei Changshan Biochemical Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with RCETH (BY) and UZPHARM (UZ). Its GMP standing is certified by UZPHARM (UZ), US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 5 April 2024 as NAI.

2
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
2
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 5 April 2024 NAI US FDA
  • 17 April 2015 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Shijiazhuang, China Not on file
China, China 3010849972

What they file, and where

Molecule Regulators Docs
Heparin Sodium EDQM, US FDA 2
Enoxaparin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
RCETH (BY) 1 None
UZPHARM (UZ) 1 1
US FDA None 1
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Hebei Changshan Biochemical Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 5 April 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates